Patents by Inventor Geun-Joong Kim

Geun-Joong Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365978
    Abstract: Provided is a recombinant expression vector containing a hybrid signal sequence and a method for secretory production of a human insulin-like growth factor-1 using the same. A heterologous signal sequence that significantly improves secretory expression of the human insulin-like growth factor-1 (hIGF1) is introduced into Komagataella phaffii, which is a unicellular eukaryotic cell, used as a host, such that various types of available signal sequences may be secured, and significantly improved secretion productivity may be achieved.
    Type: Application
    Filed: December 7, 2022
    Publication date: November 16, 2023
    Inventors: Geun-Joong KIM, Dae-Eun CHEONG
  • Publication number: 20230340049
    Abstract: Provided is a method of preparing a circular permutation (CP)-based functional recombinant human-derived fibroblast growth factor 7 and a use thereof. The fibroblast growth factor 7 to which a circular permutation is applied (CP-hFGF7115-114) is independently expressed in a host cell, such that soluble overexpression of the fibroblast growth factor 7 may be induced without causing problems according to the related art, such as lower expression level and stability compared to those of a wild-type hFGF7 protein and amino acid changes in a process of removing a fusion tag.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 26, 2023
    Inventors: Geun-Joong KIM, Hye-Ji CHOI, Dae-Eun CHEONG, Su-Kyoung YOO, Hanui LEE
  • Publication number: 20230143972
    Abstract: An NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. The enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 11, 2023
    Inventors: Geun Joong KIM, Hun-Dong LEE, Su-Kyoung YOO, Dae Eun CHEONG, Chul-Ho YUN, Hye-Ji CHOI, Sang-Oh AHN
  • Publication number: 20230119241
    Abstract: A method of expressing hydrophobin in a soluble form and a method of purifying hydrophobin, and more particularly, to a method of expressing a recombinant fusion protein including hydrophobin in a soluble form in a host cell and then purifying the expressed recombinant fusion protein are provided.
    Type: Application
    Filed: November 17, 2022
    Publication date: April 20, 2023
    Inventors: Geun Joong KIM, Dae Eun CHEONG, Ho-Dong LIM, Sang-Oh AHN, Sung Hwan YOU
  • Patent number: 11608366
    Abstract: A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ?ssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 21, 2023
    Assignees: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: Geun Joong Kim, Hye Ji Choi, Dae Eun Cheong, Su Kyoung Yoo, Dong Hyun Lee, Jae Hong Park, Jung Hyun Lee, Hyung Soon Yim, Young Jun An, Kyeong Won Lee
  • Publication number: 20220313633
    Abstract: A composition according to an embodiment of the present disclosure includes a N-phenyl-methylsulfonamido-acetamide compound represented by Formula 1. The composition may inhibit osteoclast differentiation and/or formation and exhibit excellent prophylactic or therapeutic effects on various bone diseases including periodontitis and the like. A method for treating a bone disease caused by hyperdifferentiation of osteoclasts according to an embodiment of the present disclosure includes administering to a subject in need thereof the composition.
    Type: Application
    Filed: July 13, 2020
    Publication date: October 6, 2022
    Inventors: Tae Hoon LEE, Sun Woo LEE, Eun Jin CHO, Sang Hyun MIN, Geun Joong KIM, Dong Kyu CHOI
  • Publication number: 20220274935
    Abstract: A composition according to an embodiment of the present disclosure includes a compound represented by Formula 1. The composition may inhibit osteoclast differentiation and/or formation and exhibit excellent prophylactic or therapeutic effects on various bone diseases including periodontitis and the like. A method for treating a bone disease caused by hyperdifferentiation of osteoclasts according to an embodiment of the present disclosure includes administering to a subject in need thereof the composition.
    Type: Application
    Filed: July 14, 2020
    Publication date: September 1, 2022
    Inventors: Tae Hoon LEE, Sun Woo LEE, Geun Joong KIM, Eun Jin CHO, Zhihao CHEN, Mina DING, Sang Hyun MIN, Dong Kyu CHOI
  • Publication number: 20220267742
    Abstract: The present invention relates to an NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. In the present invention, the enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 25, 2022
    Inventors: Geun Joong KIM, Hun-Dong LEE, Su-Kyoung YOO, Dae Eun CHEONG, Chul-Ho YUN, Hye-Ji CHOI, Sang-Oh AHN
  • Patent number: 11236309
    Abstract: A recombinant vector according to an embodiment of the present invention may be used for producing a reconstituted cytochrome P450 oxygenase-reductase fusion protein. Oxygenase and reductase may be independently expressed in a host cell into which the recombinant vector is introduced, and then may be fused with a split intein so that it is possible to increase the heme content contained in the active site of the oxygenase and improve enzyme activity and stability.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: February 1, 2022
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Chul Ho Yun, Dae Eun Cheong, Su Kyoung Yoo, Hye Ji Choi, Thien Kim Le
  • Publication number: 20210363199
    Abstract: A method of expressing hydrophobin in a soluble form and a method of purifying hydrophobin, and more particularly, to a method of expressing a recombinant fusion protein including hydrophobin in a soluble form in a host cell and then purifying the expressed recombinant fusion protein are provided.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 25, 2021
    Inventors: Geun Joong KIM, Dae Eun CHEONG, Ho-Dong LIM, Sang-Oh AHN
  • Publication number: 20210355456
    Abstract: A recombinant vector according to an embodiment of the present invention may be used for producing a reconstituted cytochrome P450 oxygenase-reductase fusion protein. Oxygenase and reductase may be independently expressed in a host cell into which the recombinant vector is introduced, and then may be fused with a split intein so that it is possible to increase the heme content contained in the active site of the oxygenase and improve enzyme activity and stability.
    Type: Application
    Filed: August 17, 2020
    Publication date: November 18, 2021
    Inventors: Geun Joong KIM, Chul Ho YUN, Dae Eun CHEONG, Su Kyoung YOO, Hye Ji CHOI, Thien Kim Le
  • Publication number: 20210355182
    Abstract: A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ?ssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state, due to when not utilizing tags such as an existing fusion partner there is no change in the amino acid, which is a problem generated in the removal process.
    Type: Application
    Filed: August 19, 2020
    Publication date: November 18, 2021
    Inventors: Geun Joong KIM, Hye Ji CHOI, Dae Eun CHEONG, Su Kyoung YOO, Dong Hyun LEE, Jae Hong PARK, Jung Hyun LEE, Hyung Soon YIM, Young Jun AN, Kyeong Won LEE
  • Patent number: 10704193
    Abstract: Provided is a reduction dyeing method for indigo color using Nesterenkonia sp. KDB2, KDB3 and/or KDB4. The reduction dyeing method is relatively simple, efficient and allows good reproducibility, by using Nesterenkonia sp. KDB2, KDB3 and/or KDB4 bacterial strains instead of a traditional fermentation process which entails poor reproducibility and is exacting and complicated.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: July 7, 2020
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Youn Sook Shin, Geun-Joong Kim, Eun Sil Choi, Kyung Hee Son
  • Patent number: 10308973
    Abstract: Provided is a real-time imaging method of NAPDH-dependent metabolic activity in a cell and a use thereof, and more particularly, an imaging method capable of measuring concentration gradient and change in an intracellular coenzyme using a mutant of metagenome-derived blue fluorescent protein (mBFP) in real-time and an application method thereof. In particular, the method of imaging and quantifying the coenzyme contained in various biological samples may be performed by improving fluorescence in a short time even under anaerobic conditions, without adding a substrate required for coenzyme measurement or conversion without destroying cells, and without consuming the time required for formation of a special structure (fluorophore) for generating fluorescence unlike the existing quantitative systems.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: June 4, 2019
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Geun-Joong Kim, Eung Sam Kim, Jeong Sun Kim, Sung Hwan You, Dae Eun Cheong, Eun Seo Jo
  • Patent number: 10227595
    Abstract: Provided is a ramp tag capable of solving instability in translation rate resulting from poor compatibility between codons in a foreign gene and a host when expressing a recombinant protein in E. coli. Unlike the conventional codon optimization or codon deoptimization method for solving the problem of rare codons, the present invention increases an expression efficiency of a target protein by merely having the ramp tag be fused with a target gene or independently expressed, without changing the original codon sequence, thereby allowing tRNA to be reused. Thus, the present invention provides a novel method for increasing recombinant protein expression which is capable of reducing costs and time in comparison to the codon optimization method that artificially synthesizes DNA sequences. Therefore, it is expected that the method of the present invention will be able to be used in production of high value-added pharmaceuticals or industrial enzymes.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: March 12, 2019
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun-Joong Kim, Won Ji Park, Sung-Hwan You, Jin-Young Lee, Eun-Bin Lee, Sa-Young Min
  • Patent number: 10130712
    Abstract: A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli (E. coli), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 20, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Jin-Young Lee, Sa-Young Min, Sung-Hwan You, Jung-Joon Min
  • Publication number: 20180251938
    Abstract: Provided is a reduction dyeing method for indigo using Dietzia sp. KDB1. The reduction dyeing method is relatively simple, efficient and allows good reproducibility, by using a Dietzia sp. KDB1 bacterial strain instead of a traditional fermentation process which entails poor reproducibility and is exacting and complicated. The method has the advantage of being able to substantially contribute to the field of dyeing using indigo, as the method can be used not only with natural indigo but also with synthetic indigo and makes it possible to efficiently increase the dye uptake of fabrics, and makes it possible to simplify difficult reducing processes including existing fermentation conditions which are exacting and complicated.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Applicant: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Youn Sook SHIN, Geun-Joong KIM, Eun Sil CHOI, Kyung Hee SON
  • Patent number: 9963708
    Abstract: A recombinant vector enables independent expression of a foreign gene without interfering with a biological circuit of a host cell. A gene encoding a guanylyl cyclase, a gene encoding cGMP receptor protein, and a regulatory nucleotide sequence to which cGMP receptor protein binds, which are derived from a microorganism, are recombined in at least one plasmid. Using the recombinant vector, a foreign gene may be independently expressed without interfering with a biological circuit of a host cell.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 8, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Eun Bin Lee, Sung Hwan You
  • Publication number: 20170354738
    Abstract: A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli (E. coli), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.
    Type: Application
    Filed: October 21, 2015
    Publication date: December 14, 2017
    Inventors: Geun Joong KIM, Jin-Young LEE, Sa-Young MIN, Sung-Hwan YOU, Jung-Joon MIN
  • Publication number: 20170002364
    Abstract: The present invention relates to recombinant a vector enabling independent expression of a foreign gene without interfering a biological circuit of a host cell, characterized in that a gene encoding a guanylyl cyclase, a gene encoding cGMP receptor protein, and a regulatory nucleotide sequence to which cGMP receptor protein binds, which are derived from a microorganism, are recombined in at least one plasmid, and a method for independent expression of a foreign gene without interfering a biological circuit of a host cell by using the aforementioned recombinant vector.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 5, 2017
    Inventors: Geun Joong KIM, Eun Bin LEE, Sung Hwan YOU